middle.news
Syntara Unveils New Phase 2 Data for Myelofibrosis Drug in Investor Webinar
8:38am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
Syntara Unveils New Phase 2 Data for Myelofibrosis Drug in Investor Webinar
8:38am on Friday 13th of June, 2025 AEST
Key Points
Investor webinar scheduled for 13 June 2025 to discuss Phase 2 interim data
SNT-5505 targets myelofibrosis with Fast Track and Orphan Drug designations
Data to be presented at European Hematology Association 2025 Congress
SNT-5505 studied in combination with JAK inhibitor for suboptimal responders
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE